History of COVID-19 vaccine development

Biophytis announces next regulatory steps in Europe and the United States for its COVA project

Retrieved on: 
星期二, 八月 22, 2023
Euronext Growth, CET, Therapy, Marketing, European Medicines Agency, Ageing, Trial of the century, History of COVID-19 vaccine development, EMA, Food and Drug Administration, COVID-19, Patient, FDA, Notifiable disease, Food, Vaccine

After filing requests for pre-submission meetings with both agencies in recent weeks, the company will now request a scientific advice meeting in Europe and a Type B meeting in the United States.

Key Points: 
  • After filing requests for pre-submission meetings with both agencies in recent weeks, the company will now request a scientific advice meeting in Europe and a Type B meeting in the United States.
  • The purpose of these meetings will be to gather recommendations from the EMA and the FDA to fine-tune COVA's development plan prior to marketing approval.
  • Biophytis will also present the agencies with the possibility of extending the scope of its indication to viral respiratory pathologies other than Covid-19, notably influenza, based on its non-specific mechanism of action.
  • This extension would significantly increase the number of patients eligible for treatment and optimize the commercial potential of Sarconeos (BIO101).

TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine

Retrieved on: 
星期一, 六月 26, 2023
Vaccine, GLP, Cleveland Clinic, Asthma, University, PI, Diabetes, TFF, History of COVID-19 vaccine development, Ferret, SBIR, National Institute of Allergy and Infectious Diseases, Respiratory system, Research, University of Georgia, Bangladesh Technical Education Board, CDC, Nose, Death, Immune system, Toxicology, Viral, NIAID, Cleveland, IND, Infection

FORT WORTH, Texas, June 26, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded the Company a Direct to Phase II Small Business Innovation Research (SBIR) grant of approximately $2.97 million to continue development of a novel, pan-flu multivariant mucosal vaccine using the Company’s Thin Film Freezing technology.

Key Points: 
  • If successful, this work could provide a first-in-class stable, easy-to-transport and easy-to-stockpile vaccine that would overcome the vaccine failures that result from mishandling, mismatches between predicted and actual seasonal flu strains, and evolutionary changes in influenza viruses across the season.
  • “The advancement of this program is a result of a highly productive, multi-year collaboration between TFF Pharmaceuticals and world-renowned vaccine researcher Dr. Ted Ross, Global Director of Vaccine Development at Cleveland Clinic,” said Dr. Dale Christensen, VP of Preclinical Development at TFF Pharmaceuticals.
  • “A shelf-stable mucosal formulation will revolutionize the public health approach, providing an influenza vaccine that is effective regardless of which strain emerges in any given year.
  • “Based on positive data generated in collaboration with TFF Pharmaceuticals, we are moving closer to achieving our goal of developing a universal influenza vaccine to protect all patient populations in the US and globally.”

Growth Opportunities in Supply Chain Monitoring, Vaccine Development, COVID Diagnosis, and Wireless Charged Wearable Devices - ResearchAndMarkets.com

Retrieved on: 
星期一, 十月 10, 2022
Health, Pharmaceutical, Inside, Insurance, Electronics, Intelligence, Patient, Biotechnology, Farmer, Perspiration, Automation, Sport, Diagnosis, Health, Blockchain, History of COVID-19 vaccine development, Athlete, Skin, TOE, COVID-19, Wireless, Weather

The "Growth Opportunities in Supply Chain Monitoring, Vaccine Development, COVID Diagnosis, and Wireless Charged Wearable Devices" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Supply Chain Monitoring, Vaccine Development, COVID Diagnosis, and Wireless Charged Wearable Devices" report has been added to ResearchAndMarkets.com's offering.
  • The TOE also covers innovations based on the use of blockchain to provide precise weather insights and insurance services to small-scale farmers.
  • The TOE additionally provides insights on the use of 3-D printed wireless charged wearable devices that can be used by patients and sports athletes.
  • Innovations Opportunities in Supply Chain Monitoring, and Wireless Charged Wearable Devices